Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Beiersdorf AG | UNKNOWN |
Recent clinical studies showed, that a hydrocolloid patch is effective, well tolerated and comparable with aciclovir cream 5 % for the treatment of HSL lesions, while affording additional benefits of wound protection, discretion and relief of social embarrassment. The aim of the actual study was the clinical assessment of the effectiveness and safety of Hansaplast® SOS Herpes Patch (HPHP) in comparison to Compeed® Herpes Vesicle Patch (CHP) in treating HSL. Both products are CE-certificated and are available at the market for medical devices.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Herpes Patch SOS (Hansaplast®) | Active Comparator |
| |
| Herpes vesicle patch of Compeed® | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Herpes Patch SOS (Hansaplast®) | Other |
| ||
| Herpes vesicle patch of Compeed® |
| Measure | Description | Time Frame |
|---|---|---|
| The primary endpoint of this study was the Subjects Global Assessment of Therapy (SGAT) at final visit. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with healed HSL lesions on day 5 and day 10 (assessed by clinician) | ||
| Blinded clinician global assessment (IGAT) at the end of therapy. | ||
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Carl Gustav Carus at the Technische Universität Dresden | Dresden | Saxony | 01307 | Germany |
Not provided
| Other |
|
| Development of lesion size. |
| The number of study subjects with vesicles at onset of the study and at visit 2 and the final visit 3. |
| Clinician-assessed lesion stage at onset of the study and at visit 2 and the final visit 3. |
| Clinician-assessed time to complete healing from begin of the study. |
| Time to complete healing of HSL after beginning of signs and symptoms. |
| Assessment of the local compatibility by patient and by investigator. |
| The severity and duration of subject-assessed individual signs and symptoms. |
| ID | Term |
|---|---|
| D006560 | Herpes Labialis |
| ID | Term |
|---|---|
| D006561 | Herpes Simplex |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D017193 | Skin Diseases, Viral |
| D008047 | Lip Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D012874 | Skin Diseases, Infectious |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided